Federico Pulido

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

François Raffi, Anita Rachlis, Hans‐Jürgen Stellbrink et al. · The Lancet · 2013 · 537 citations

Week Results, Treatment And Prevention, Human Retrovirus +8

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · The Lancet · 2018 · 371 citations · Full text

Hiv/aids Counselling, Treatment And Prevention, Week 48 +14

The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml

José Ramón Arribas, Andrzéj Horban, Jan Gerstoft et al. · AIDS · 2009 · 183 citations

Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain

Deanna Kerrigan, Andrea Mantsios, Miguel Górgolas et al. · PLoS ONE · 2018 · 163 citations · Full text

Sustained Virological Response to Interferon Plus Ribavirin Reduces Non-Liver-Related Mortality in Patients Coinfected With HIV and Hepatitis C Virus

Juan Berenguer, Elisa Boucourt Rodríguez, Pilar Miralles et al. · Clinical Infectious Diseases · 2012 · 159 citations · Full text